K Krüger1, K Albrecht, S Rehart, R Scholz. 1. Niedergelassener Rheumatologe, Praxiszentrum, Sankt-Bonifatius, 81541, München, Deutschland, klaus.krueger@med.uni-muenchen.de.
Abstract
BACKGROUND: The perioperative administration of antirheumatic medication can lead to an increased risk of infection and to a malfunction in wound healing up to a manifest infection; however, the termination of antirheumatic therapy can result in a flare up of the disease. Both situations can endanger the success of the operation, particularly in arthroplasty. METHOD: The recommendations have been developed and approved by the Pharmacotherapy Commission of the German Society for Rheumatology following a systematic literature search (as of 30 April 2013) and a consensus process. RESULTS: As very little data with sufficiently high evidence are available, the present recommendations should be considered as having an advisory quality and an individual risk assessment should always be carried out. Classical disease-modifying antirheumatic drugs (DMARD), such as methotrexate can be continued in normal cases but whether this is also true for leflunomide is still undecided. For biologicals a break of two half-life periods before the operation is recommended. The therapy can be continued after wound healing has been completed and when there are no signs of infection.
BACKGROUND: The perioperative administration of antirheumatic medication can lead to an increased risk of infection and to a malfunction in wound healing up to a manifest infection; however, the termination of antirheumatic therapy can result in a flare up of the disease. Both situations can endanger the success of the operation, particularly in arthroplasty. METHOD: The recommendations have been developed and approved by the Pharmacotherapy Commission of the German Society for Rheumatology following a systematic literature search (as of 30 April 2013) and a consensus process. RESULTS: As very little data with sufficiently high evidence are available, the present recommendations should be considered as having an advisory quality and an individual risk assessment should always be carried out. Classical disease-modifying antirheumatic drugs (DMARD), such as methotrexate can be continued in normal cases but whether this is also true for leflunomide is still undecided. For biologicals a break of two half-life periods before the operation is recommended. The therapy can be continued after wound healing has been completed and when there are no signs of infection.
Authors: D Wendling; J-C Balblanc; A Brousse; A Lohse; G Lehuede; P Garbuio; E Toussirot; B Auge; D Jacques Journal: Ann Rheum Dis Date: 2005-09 Impact factor: 19.103
Authors: Claire Bombardier; Glen S Hazlewood; Pooneh Akhavan; Orit Schieir; Anne Dooley; Boulos Haraoui; Majed Khraishi; Sharon A Leclercq; Jean Légaré; Dianne P Mosher; James Pencharz; Janet E Pope; John Thomson; Carter Thorne; Michel Zummer; Michael A Gardam; Johan Askling; Vivian Bykerk Journal: J Rheumatol Date: 2012-06-15 Impact factor: 4.666
Authors: Tim Bongartz; Christine S Halligan; Douglas R Osmon; Megan S Reinalda; William R Bamlet; Cynthia S Crowson; Arlen D Hanssen; Eric L Matteson Journal: Arthritis Rheum Date: 2008-12-15
Authors: A Ruyssen-Witrand; L Gossec; C Salliot; M Luc; M Duclos; S Guignard; M Dougados Journal: Clin Exp Rheumatol Date: 2007 May-Jun Impact factor: 4.473
Authors: U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking Journal: Z Rheumatol Date: 2019-12 Impact factor: 1.372